{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:35:24Z","timestamp":1791110124295,"version":"4.1.0"},"reference-count":248,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.survophthal.2010.08.006","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T06:20:06Z","timestamp":1297923606000},"page":"95-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":246,"title":["Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease"],"prefix":"10.1016","volume":"56","author":[{"given":"Michael","family":"Tolentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib1","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1167\/iovs.06-0942","article-title":"Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome)","volume":"48","author":"Abbott","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/bbrc.1993.1671","article-title":"Synthesis and secretion of vascular permeability factor\/vascular endothelial growth factor by human retinal pigment epithelial cells","volume":"193","author":"Adamis","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.survophthal.2010.08.006_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib6","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","article-title":"Hypoxic regulation of vascular endothelial growth factor in retinal cells","volume":"113","author":"Aiello","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00417-006-0471-7","article-title":"Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration","volume":"245","author":"Aisenbrey","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaapos.2009.03.006","article-title":"Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema","volume":"13","author":"Al-Dhibi","year":"2009","journal-title":"J AAPOS"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib9","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"issue":"6921","key":"10.1016\/j.survophthal.2010.08.006_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results","volume":"145","author":"Antoszyk","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety\u2013pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Apte","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ymthe.2004.08.007","article-title":"Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo","volume":"10","author":"Arsic","year":"2004","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.survophthal.2010.08.006_bib15","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","article-title":"VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells","volume":"18","author":"Asahara","year":"1999","journal-title":"EMBO J"},{"issue":"37","key":"10.1016\/j.survophthal.2010.08.006_bib16","doi-asserted-by":"crossref","first-page":"26746","DOI":"10.1074\/jbc.M705200200","article-title":"Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing","volume":"282","author":"Athanasopoulos","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.survophthal.2010.08.006_bib17","article-title":"Full prescribing information","year":"2008","journal-title":"Genentech, Inc"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib18","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1167\/iovs.08-2871","article-title":"Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits","volume":"50","author":"Avci","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/eye.2009.143","article-title":"Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet\u2019s disease","volume":"24","author":"Bae","year":"2010","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jfo.2009.04.001","article-title":"[Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study]","volume":"32","author":"Baeteman","year":"2009","journal-title":"J\u00a0Fr Ophtalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib22","doi-asserted-by":"crossref","first-page":"H547","DOI":"10.1152\/ajpheart.00616.2005","article-title":"Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling","volume":"290","author":"Baffert","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajo.2006.03.058","article-title":"Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model","volume":"142","author":"Bakri","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00417-008-0819-2","article-title":"Persistent ocular hypertension following intravitreal ranibizumab","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.eye.6702938","article-title":"Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab","volume":"23","author":"Bakri","year":"2009","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib27","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336","article-title":"Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1","volume":"87","author":"Barleon","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2009.02.006","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study","volume":"148","author":"Bashshur","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3928\/15428877-20100303-06","article-title":"The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation","volume":"41","author":"Batman","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tins.2006.03.005","article-title":"Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors","volume":"29","author":"Bazan","year":"2006","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9440(10)65138-3","article-title":"Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation","volume":"155","author":"Blaauwgeers","year":"1999","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic vascular endothelial cells become procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib33","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2010.08.006_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/OPTH.S4641","article-title":"Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by contralateral sympathetic ophthalmia","volume":"3","author":"Brouzas","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"14","key":"10.1016\/j.survophthal.2010.08.006_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1755-3768.2008.01216.x","article-title":"Transient global amnesia following intravitreal injection of bevacizumab","volume":"87","author":"Byeon","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273970903567626","article-title":"Isolated sixth nerve palsy after intravitreal bevacizumab injection","volume":"18","author":"Cakmak","year":"2010","journal-title":"Strabismus"},{"issue":"33","key":"10.1016\/j.survophthal.2010.08.006_bib39","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6573","key":"10.1016\/j.survophthal.2010.08.006_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.69.6.397","article-title":"Retinal pigment epithelial detachments in the elderly: classification and outcome","volume":"69","author":"Casswell","year":"1985","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib42","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/IAE.0b013e3181babda5","article-title":"Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections","volume":"30","author":"Chan","year":"2010","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/IAE.0b013e3180cc2612","article-title":"Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration","volume":"27","author":"Chan","year":"2007","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/IAE.0b013e3180a032db","article-title":"Tears of the retinal pigment epithelium: an old problem in a new era","volume":"27","author":"Chang","year":"2007","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib46","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/bjo.2007.129627","article-title":"Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia","volume":"92","author":"Charbel Issa","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/IAE.0b013e318154b9f2","article-title":"Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections","volume":"27","author":"Charles","year":"2007","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3928\/15428877-20090101-04","article-title":"Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema","volume":"40","author":"Chen","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib50","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/IAE.0b013e31817d5d03","article-title":"Predictors of anti-VEGF\u2013associated retinal pigment epithelial tear using FA and OCT analysis","volume":"28","author":"Chiang","year":"2008","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib51","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","article-title":"A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema","volume":"113","author":"Chun","year":"2006","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib52","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/eye.2010.22","article-title":"Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology","volume":"24","author":"Chung","year":"2010","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/ICU.0b013e32832d25b3","article-title":"Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"20","author":"Ciulla","year":"2009","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.172.6.1535","article-title":"Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration","volume":"172","author":"Clauss","year":"1990","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","article-title":"Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice","volume":"8","author":"Compernolle","year":"2002","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib56","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00125-007-0670-8","article-title":"Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs","volume":"50","author":"Cross","year":"2007","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib57","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.exer.2004.01.010","article-title":"Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor","volume":"78","author":"Csaky","year":"2004","journal-title":"Exp Eye Res"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib58","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double\u2013masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.02.027","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"D\u2019Amico","year":"2006","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2007.05.006","article-title":"Safety of intravitreal injections in patients receiving warfarin anticoagulation","volume":"144","author":"Dayani","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/sj.gt.3301697","article-title":"Recombinant AAV vector encoding human VEGF165 enhances wound healing","volume":"9","author":"Deodato","year":"2002","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","article-title":"Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation","volume":"174","author":"Dikov","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1073\/pnas.0607542104","article-title":"Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis","volume":"104","author":"Dorrell","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib64","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"Drolet","year":"2000","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ophtha.2006.07.045","article-title":"Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans","volume":"114","author":"Duan","year":"2007","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041552-200401000-00002","article-title":"The role of VEGF-A in glomerular development and function","volume":"13","author":"Eremina","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1\u20132","key":"10.1016\/j.survophthal.2010.08.006_bib67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0006-8993(02)03766-6","article-title":"Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina","volume":"969","author":"Famiglietti","year":"2003","journal-title":"Brain Res"},{"issue":"6573","key":"10.1016\/j.survophthal.2010.08.006_bib68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib69","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib72","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/IAE.0b013e3181884fd2","article-title":"Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab","volume":"28","author":"Fintak","year":"2008","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib73","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/jop.2006.0149","article-title":"Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit","volume":"23","author":"Foy","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib74","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jc.2004-1572","article-title":"Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function","volume":"90","author":"Fraser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib75","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1076\/ceyr.16.7.663.5061","article-title":"Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume","volume":"16","author":"Friedrich","year":"1997","journal-title":"Curr Eye Res"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib76","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bjo.2009.174946","article-title":"Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study","volume":"94","author":"Friberg","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography\u2013guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib78","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib79","doi-asserted-by":"crossref","DOI":"10.3928\/15428877-20100215-57","article-title":"Hemorrhagic macular infarction after intravitreal bevacizumab for central retinal vein occlusion","author":"Furino","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib80","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00417-007-0551-3","article-title":"RPE rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD","volume":"245","author":"Gamulescu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2009.0126","article-title":"Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration","volume":"26","author":"Gamulescu","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib82","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00417-009-1184-5","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum","volume":"247","author":"Ganssauge","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7070","key":"10.1016\/j.survophthal.2010.08.006_bib83","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nature04482","article-title":"Retinal angiogenesis in development and disease","volume":"438","author":"Gariano","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib84","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib85","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bjo.2008.138479","article-title":"Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)","volume":"93","author":"Georgopoulos","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib86","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib87","first-page":"748","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"356","author":"Gillies","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib88","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","article-title":"Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure","volume":"18","author":"Gismondi","year":"2009","journal-title":"J Glaucoma"},{"issue":"Suppl 3","key":"10.1016\/j.survophthal.2010.08.006_bib89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib90","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.ophtha.2009.07.027","article-title":"Bevacizumab local complications","volume":"116","author":"Gordon-Angelozzi","year":"2009","journal-title":"Ophthalmology"},{"issue":"27","key":"10.1016\/j.survophthal.2010.08.006_bib91","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib92","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/112067211002000235","article-title":"Full-thickness macular hole after intravitreal injection of ranibizumab in a patient with retinal pigment epithelium detachment and tear","volume":"20","author":"Grigoropoulos","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib93","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archopht.118.5.625","article-title":"Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy","volume":"118","author":"Grossniklaus","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib94","first-page":"119","article-title":"Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization","volume":"8","author":"Grossniklaus","year":"2002","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib95","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jcp.1041640219","article-title":"Vasculotropin\/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro","volume":"164","author":"Guerrin","year":"1995","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib96","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1167\/iovs.06-1171","article-title":"Penetration of bevacizumab through the retina after intravitreal injection in the monkey","volume":"48","author":"Heiduschka","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib97","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study","volume":"124","author":"Heier","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib98","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","article-title":"MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis","volume":"2","author":"Hiratsuka","year":"2002","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/WNO.0b013e3181a58fd1","article-title":"Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab","volume":"29","author":"Hosseini","year":"2009","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib101","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000235726","article-title":"Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome","volume":"224","author":"Huang","year":"2010","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib102","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3928\/15428877-20061101-01","article-title":"Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration","volume":"37","author":"Hughes","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib103","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","article-title":"Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes","volume":"48","author":"Inan","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib104","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1167\/iovs.02-0807","article-title":"Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization","volume":"44","author":"Ishida","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.20022027","article-title":"VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization","volume":"198","author":"Ishida","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib106","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3129\/i10-013","article-title":"Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study","volume":"45","author":"Johnson","year":"2010","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib108","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3129\/i09-247","article-title":"Tonic-clonic seizures following intravitreal bevacizumab injection","volume":"45","author":"Johnson","year":"2010","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib109","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1755-3768.2008.01225.x","article-title":"Progression of tractional retinal detachment following intravitreal bevacizumab","volume":"87","author":"Jonas","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3928\/15428877-20090430-12","article-title":"Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections","volume":"40","author":"Kahook","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib111","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib112","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000213644","article-title":"Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab","volume":"223","author":"Karagiannis","year":"2009","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib114","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF receptors causes lung cell apoptosis and emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0420.2006.00819.x","article-title":"Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure","volume":"85","author":"Kernt","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib116","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/09286580801939320","article-title":"Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease","volume":"15","author":"Khan","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib117","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1167\/iovs.04-0087","article-title":"Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid","volume":"47","author":"Kim","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib118","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/01.iae.0000237080.10627.b7","article-title":"Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab","volume":"26","author":"Kiss","year":"2006","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib119","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI119416","article-title":"Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis","volume":"99","author":"Kitamoto","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib120","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/j.1755-3768.2008.01336.x","article-title":"Intravitreal silicone oil droplets following pegaptanib injection","volume":"88","author":"Kocabora","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib121","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1755-3768.2009.01612.x","article-title":"Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome","volume":"88","author":"Kofoed","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2009.01547.x","article-title":"Retinal pigment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age-related macular degeneration","volume":"88","author":"Konstantinidis","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00347-007-1561-6","article-title":"[Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress]","volume":"105","author":"Kook","year":"2008","journal-title":"Ophthalmologe"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib124","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1442-9071.2009.02043.x","article-title":"Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization","volume":"37","author":"Krishnan","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib125","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/eye.2008.179","article-title":"Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment","volume":"23","author":"Krishnan","year":"2009","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib126","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib127","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment","volume":"120","author":"Krzystolik","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib128","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","article-title":"Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections","volume":"29","author":"Ladas","year":"2009","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00417-009-1171-x","article-title":"Fever after intravitreal anti-VEGF injections","volume":"248","author":"Ladas","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0070-2153(04)62007-2","article-title":"Genetics in zebrafish, mice, and humans to dissect congenital heart disease: insights in the role of VEGF","volume":"62","author":"Lambrechts","year":"2004","journal-title":"Curr Top Dev Biol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/mvre.1997.2056","article-title":"Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro","volume":"55","author":"Lamoreaux","year":"1998","journal-title":"Microvasc Res"},{"issue":"1\u20132","key":"10.1016\/j.survophthal.2010.08.006_bib133","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1021588227705","article-title":"Serum and plasma levels of FGF-2 and VEGF in healthy blood donors","volume":"5","author":"Larsson","year":"2002","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib134","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":"Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity","volume":"156","author":"Lashkari","year":"2000","journal-title":"Am J Pathol"},{"issue":"5608","key":"10.1016\/j.survophthal.2010.08.006_bib135","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.1079562","article-title":"Angiogenesis-independent endothelial protection of liver: role of VEGFR-1","volume":"299","author":"LeCouter","year":"2003","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib136","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","article-title":"A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection","volume":"29","author":"Lee","year":"2009","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib137","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib138","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1083\/jcb.200409115","article-title":"Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors","volume":"169","author":"Lee","year":"2005","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib139","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/jop.2008.0092","article-title":"Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy","volume":"25","author":"Lee","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4935","key":"10.1016\/j.survophthal.2010.08.006_bib140","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib141","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/IAE.0b013e318154b9b9","article-title":"Multifocal electroretinography in patients with exudative AMD and intravitreal treatment with pegaptanib sodium","volume":"27","author":"Lipski","year":"2007","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib142","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0003-4975(01)03404-X","article-title":"Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery","volume":"73","author":"Liu","year":"2002","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib143","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3928\/15428877-20091230-13","article-title":"Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy","volume":"41","author":"Liu","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib144","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0029-1245225","article-title":"Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation","volume":"227","author":"Loukopoulos","year":"2010","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2010.08.006_bib145","series-title":"Lucentis (ranibizumab injection). Full prescribing information","year":"2010"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib146","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjo.2006.111260","article-title":"The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator","volume":"91","author":"L\u00fcke","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib147","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.iae.0000222547.35820.52","article-title":"Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells","volume":"26","author":"Luthra","year":"2006","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib148","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.survophthal.2010.08.006_bib149","series-title":"Macugen (pegaptanib sodium injection). U.S. full prescribing information","year":"2008"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib150","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1755-3768.2009.01535.x","article-title":"Retinal vascular events after intravitreal bevacizumab","volume":"88","author":"Mansour","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib151","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","article-title":"Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function","volume":"167","author":"Marneros","year":"2005","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib152","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0002-9440(10)64964-4","article-title":"Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia","volume":"156","author":"Marti","year":"2000","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib153","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/IAE.0b013e3181633fee","article-title":"Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection","volume":"28","author":"Mason","year":"2008","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib154","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","article-title":"Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Maturi","year":"2006","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib155","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1182\/blood.V93.11.3811","article-title":"Vascular endothelial cell growth factor\u2013induced tissue factor expression in endothelial cells is mediated by EGR-1","volume":"93","author":"Mechtcheriakova","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib156","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1600-0420.2007.00926.x","article-title":"Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin(tm)) injections","volume":"85","author":"Mennel","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib157","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jcu.20650","article-title":"Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration","volume":"38","author":"Mete","year":"2010","journal-title":"J Clin Ultrasound"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib158","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archopht.125.7.994","article-title":"Preoperative management of anticoagulated patients undergoing repeated intravitreal injections","volume":"125","author":"Meyer","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib159","article-title":"Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after single intravitreal injection in humans","author":"Meyer","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajo.2006.08.003","article-title":"Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration","volume":"143","author":"Meyer","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib161","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bjo.2006.093732","article-title":"Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration","volume":"90","author":"Meyer","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib162","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.22129","article-title":"Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells","volume":"224","author":"Miki","year":"2010","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib163","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","article-title":"Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2","volume":"56","author":"Mimura","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"10.1016\/j.survophthal.2010.08.006_bib164","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1242\/dev.127.18.3941","article-title":"Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression","volume":"127","author":"Miquerol","year":"2000","journal-title":"Development"},{"issue":"14","key":"10.1016\/j.survophthal.2010.08.006_bib165","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jama.297.14.1538","article-title":"Study aims to clarify efficacy, safety of eye drug treatments","volume":"297","author":"Mitka","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib166","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00417-008-0914-4","article-title":"Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy","volume":"246","author":"Moradian","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib167","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3928\/15428877-20091030-06","article-title":"Optical coherence tomography predictors of retinal pigment epithelial tear following intravitreal bevacizumab injection","volume":"40","author":"Moroz","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.survophthal.2010.08.006_bib168","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10792-007-9152-8","article-title":"Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin)","volume":"28","author":"Neri","year":"2008","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib169","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0008-4182(05)80078-X","article-title":"Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration","volume":"40","author":"Ng","year":"2005","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib171","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib172","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib173","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib174","first-page":"1445","article-title":"Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing","volume":"152","author":"Nissen","year":"1998","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u2014in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib176","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/88842","article-title":"Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration","volume":"28","author":"Oosthuyse","year":"2001","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib177","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2009.03.017","article-title":"Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration","volume":"116","author":"Papadopoulou","year":"2009","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib178","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1172\/JCI119868","article-title":"Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells","volume":"100","author":"Papapetropoulos","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib179","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00281-008-0112-9","article-title":"Immunopathological aspects of age-related macular degeneration","volume":"30","author":"Patel","year":"2008","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00417-002-0505-8","article-title":"Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications","volume":"240","author":"Pauleikhoff","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib181","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0006-291X(91)91276-I","article-title":"Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells","volume":"181","author":"Pepper","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib182","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ajo.2007.03.007","article-title":"Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab","volume":"143","author":"Peters","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib183","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ajo.2007.12.036","article-title":"Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting","volume":"145","author":"Pilli","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib184","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2003-07-2214","article-title":"Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells","volume":"103","author":"Prager","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib185","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/112067210901900535","article-title":"Foveal geographic atrophy following intravitreal pegaptanib sodium (Macugen) for drusenoid pigment epithelium detachment","volume":"19","author":"Querques","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib186","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1755-3768.2008.01226.x","article-title":"Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration","volume":"87","author":"Querques","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib187","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","article-title":"Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story","volume":"22","author":"Quiroz-Mercado","year":"2007","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib188","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension","volume":"23","author":"Rasier","year":"2009","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib189","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib190","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2010.08.006_bib191","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1096\/fj.00-0598fje","article-title":"Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development","volume":"15","author":"Robinson","year":"2001","journal-title":"FASEB J"},{"issue":"8","key":"10.1016\/j.survophthal.2010.08.006_bib192","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1600-0420.2007.00968.x","article-title":"Metrorrhagia after intravitreal injection of bevacizumab","volume":"85","author":"Rodrigues","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib193","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/IAE.0b013e3180cc2645","article-title":"Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"27","author":"Ronan","year":"2007","journal-title":"Retina"},{"issue":"14","key":"10.1016\/j.survophthal.2010.08.006_bib194","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000228590","article-title":"The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration","volume":"223","author":"Rouvas","year":"2009","journal-title":"Ophthalmologica"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib196","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/bjs.6100","article-title":"Vascular endothelial growth factor is associated with histological instability of carotid plaques","volume":"95","author":"Russell","year":"2008","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib197","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicol Pathol"},{"issue":"11","key":"10.1016\/j.survophthal.2010.08.006_bib198","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual functions: evidence for a survival role on M\u00fcller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.survophthal.2010.08.006_bib199","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib200","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cne.10705","article-title":"VEGF expression by ganglion cells in central retina before formation of the foveal depression in monkey retina: evidence of developmental hypoxia","volume":"462","author":"Sandercoe","year":"2003","journal-title":"J Comp Neurol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib201","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2009.07.041","article-title":"Severe intraocular inflammation after intravitreal injection of bevacizumab","volume":"117","author":"Sato","year":"2010","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib202","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00417-008-0874-8","article-title":"Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab","volume":"246","author":"Sawada","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib203","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1755-3768.2008.01291.x","article-title":"Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"87","author":"Sayanagi","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"16","key":"10.1016\/j.survophthal.2010.08.006_bib204","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib205","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"issue":"4587","key":"10.1016\/j.survophthal.2010.08.006_bib206","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib207","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib208","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/112067211002000124","article-title":"Course of intraocular pressure after intravitreal injection of 0.05 ml ranibizumab (Lucentis)","volume":"20","author":"Sharei","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib209","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","article-title":"Complications in patients after intravitreal injection of bevacizumab","volume":"86","author":"Shima","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/bjo.2009.160986","article-title":"Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease","volume":"94","author":"Shimura","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib211","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third year safety results of the V.I.S.I.O.N. trial","volume":"92","author":"Singerman","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib212","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/IAE.0b013e318195cad5","article-title":"Retinal pigment epithelial tears in ranibizumab-treated eyes","volume":"29","author":"Smith","year":"2009","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib213","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib214","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2006.095190","article-title":"Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells","volume":"90","author":"Spitzer","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000098504","article-title":"Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy","volume":"39","author":"Starita","year":"2007","journal-title":"Dev Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2010.08.006_bib216","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ajo.2006.10.007","article-title":"Vitreous injections of pegaptanib sodium triggering allergic reactions","volume":"143","author":"Steffensmeier","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2010.08.006_bib217","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","article-title":"VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection","volume":"26","author":"Storkebaum","year":"2004","journal-title":"Bioessays"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib218","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nn1360","article-title":"Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS","volume":"8","author":"Storkebaum","year":"2005","journal-title":"Nat Neurosci"},{"issue":"15","key":"10.1016\/j.survophthal.2010.08.006_bib219","doi-asserted-by":"crossref","first-page":"9656","DOI":"10.1073\/pnas.152324099","article-title":"Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover","volume":"99","author":"Street","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib220","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI200317977","article-title":"VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia","volume":"111","author":"Sun","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.survophthal.2010.08.006_bib221","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","article-title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy","volume":"460","author":"Takeda","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib222","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1152\/japplphysiol.00221.2004","article-title":"Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice","volume":"97","author":"Tang","year":"2004","journal-title":"J Appl Physiol"},{"issue":"14","key":"10.1016\/j.survophthal.2010.08.006_bib223","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/CIRCULATIONAHA.104.526954","article-title":"Vascular endothelial growth factor is required for coronary collateral growth in the rat","volume":"112","author":"Toyota","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib224","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0161-6420(98)92782-8","article-title":"Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma","volume":"105","author":"Tripathi","year":"1998","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib225","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/138945006778559111","article-title":"The many antithrombotic actions of nitric oxide","volume":"7","author":"Tziros","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib226","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.21445","article-title":"Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels","volume":"217","author":"Ueno","year":"2008","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib227","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib228","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mvre.2001.2334","article-title":"Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells","volume":"62","author":"Uhlmann","year":"2001","journal-title":"Microvasc Res"},{"issue":"12","key":"10.1016\/j.survophthal.2010.08.006_bib229","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems","volume":"293","author":"van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.survophthal.2010.08.006_bib230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/IAE.0b013e318186c64e","article-title":"The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study","volume":"29","author":"Velez-Montoya","year":"2009","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib231","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib232","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1755-3768.2008.01406.x","article-title":"Retinal artery occlusion following intravitreal anti-VEGF therapy","volume":"88","author":"von Hanno","year":"2010","journal-title":"Acta Ophthal"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib233","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.vph.2006.10.009","article-title":"Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery","volume":"46","author":"Wei","year":"2007","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"10.1016\/j.survophthal.2010.08.006_bib234","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib235","doi-asserted-by":"crossref","first-page":"591","DOI":"10.47102\/annals-acadmedsg.V37N7p591","article-title":"Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report","volume":"37","author":"Wu","year":"2008","journal-title":"Ann Acad Med Singapore"},{"issue":"6","key":"10.1016\/j.survophthal.2010.08.006_bib236","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1755-3768.2008.01281.x","article-title":"Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab","volume":"87","author":"Yoon","year":"2009","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2010.08.006_bib237","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular\u2013fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.survophthal.2010.08.006_bib238","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2010.08.006_bib239","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10792-007-9122-1","article-title":"Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG\/EOG) tests in two subgroups of patients","volume":"28","author":"Ziemssen","year":"2008","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2010.08.006_bib240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10792-008-9221-7","article-title":"Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study","volume":"29","author":"Ziemssen","year":"2009","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2010.08.006_bib241","author":"Xu"},{"key":"10.1016\/j.survophthal.2010.08.006_bib242","article-title":"Pharmacokinetics of intravitreal bevacizumab in humans","volume":"48","author":"Csaky","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2010.08.006_bib243","article-title":"Effects of intravitreal injection of pegaptanib on retinal pigment epithelium and optic nerve","volume":"48","author":"Altaweel","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2010.08.006_bib244","unstructured":"Hoffman-LaRoche, Canada. Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) Following Off-label Intravitreal Use of AVASTIN (bevacizumab). December 16, 2008. [http:\/\/www.e-med.co.il\/emed\/new\/Usersite\/Presentations\/avastin040109.pdf]. Accessed May 26, 2010"},{"key":"10.1016\/j.survophthal.2010.08.006_bib245","article-title":"Complications after intravitreal injection of antiangiogenic factors","volume":"48","author":"Callizo","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2010.08.006_bib246","unstructured":"Tezel TH: Intravitreally injected anti-VEGF drugs exert a biological effect in the fellow eye. Presented at 24th Annual Meeting of the American Society of Retina Specialists, October 6, 2006"},{"key":"10.1016\/j.survophthal.2010.08.006_bib247","unstructured":"Genentech, Inc. January 24, 2007. Dear health care provider letter [http:\/\/www.gene.com\/gene\/products\/information\/pdf\/lucentis_sailor_letter.pdf]. Accessed July 30, 2010"},{"key":"10.1016\/j.survophthal.2010.08.006_bib248","article-title":"Balancing visual acuity benefits with systemic adverse effects in anti-VEGF therapy","volume":"48","author":"Javitt","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625710001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625710001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:37:19Z","timestamp":1758541039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625710001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":248,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0039625710001578"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2010.08.006","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2010.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}